Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2Genitourinary 1

Conditions

Thyroid Cancer, Papillary 2Pituitary Neoplasms 2Adenocarcinoma, Follicular 2Thyroid Neoplasms 1Pituitary ACTH Hypersecretion 1Head and Neck Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Magnetic Resonance Spectroscopy 9Iodine-131 7Thyrotropin Alfa 5trametinib 3lenvatinib 3cabozantinib 3Sunitinib 3Specimen Handling 3Fluorodeoxyglucose F18 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3vandetanib 2dabrafenib 2X-Rays 2Trastuzumab 2Sorafenib 2Rosiglitazone 2Radiotherapy 2Interviews as Topic 2Gefitinib 2Everolimus 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1tremelimumab 1tipifarnib 1tanespimycin 1spartalizumab 1selpercatinib 1sargramostim 1romidepsin 1pembrolizumab 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Adenocarcinoma, Follicular × Rosiglitazone × Endocrine × Clear all
NCT00098852 2014-01-06

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT01100619 2013-09-19

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Exelixis

Phase 1 Completed
40 enrolled
EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Carcinoma, Renal Cell, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡